Nuvation Bio Inc. (NUVB)
| Bid | 1.94 |
| Market Cap | 665.48M |
| Revenue (ttm) | 7.87M |
| Net Income (ttm) | -567.94M |
| EPS (ttm) | -2.11 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | -3.07 |
| Analyst | Buy |
| Ask | 2.06 |
| Volume | 2,785,978 |
| Avg. Volume (20D) | 2,717,406 |
| Open | 1.90 |
| Previous Close | 1.88 |
| Day's Range | 1.89 - 2.00 |
| 52-Week Range | 1.54 - 3.97 |
| Beta | 1.47 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiat...
Analyst Forecast
According to 4 analyst ratings, the average rating for NUVB stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 408.91% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care ConferenceNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, Pre...
2 months ago · seekingalpha.com
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside CatalystNuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Appl...
